On April 17, 2026 Ensem Therapeutics, Inc. (ENSEM), a clinical-stage, oncology-focused biopharmaceutical company, reported presentations of preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held April 17–22 in San Diego, CA. The data support the differentiated preclinical profiles of ETX-929, a pan-KRAS inhibitor for the treatment of KRAS-altered solid tumors, and ETX-880, a covalent WRN inhibitor for the treatment of microsatellite instability-high (MSI-H) solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These AACR (Free AACR Whitepaper) presentations underscore the breadth and depth of ENSEM’s oncology pipeline, fueled by our proprietary Kinetic Ensemble platform," said Shengfang Jin, PhD, Co-Founder, President, and Chief Executive Officer of ENSEM. "With ETX-929 and ETX-880, we are advancing potential best-in-class small molecule inhibitors against two of the most compelling targets in oncology today—KRAS and WRN. These programs, alongside our clinical-stage PI3Kα program ETX-636, demonstrate the power of our platform to systematically tackle high-value, difficult-to-drug targets with differentiated molecules."

AACR Presentation Details

Details of the presentations are as follows:

ETX-929 (Pan-KRAS Inhibitor)

Title: ETX-929, a potential best-In-class, oral, highly potent and selective dual ON / OFF state Pan-KRAS small molecule inhibitor for the treatment of KRAS mutant and wild-type amplified cancers
Poster ID: 418
Session: Novel Antitumor Agents 1
Date/Time: 4/19/2026 2PM – 5PM PT
Location: Poster Section 17, Poster Board Number: 21
ETX-880 (Covalent WRN Inhibitor)

Title: ETX-880, a potential best-in-class, oral, highly potent and selective covalent inhibitor of Werner helicase for the treatment of microsatellite instability-high (MSI-H) cancers
Poster ID: 423
Session: Novel Antitumor Agents 1
Date/Time: 4/19/2026 2PM – 5PM PT
Location: Poster Section 17, Poster Board Number: 26
About ETX-929

ETX-929 is a potent and selective oral pan-KRAS inhibitor designed leveraging ENSEM’s proprietary Kinetic Ensemble platform. ETX-929 inhibits multiple KRAS-mutant variants, including KRASG12D, KRASG12V, KRASG12C, and other clinically relevant mutations, in both the active (GTP-bound/ON) and inactive (GDP-bound/OFF) states. KRAS is the most frequently mutated oncogene in human cancers, driving approximately 25% of all solid tumors, including pancreatic, colorectal, and non-small cell lung cancers. Despite recent advances in allele-specific KRAS inhibitors, there remains a significant unmet need for pan-KRAS therapeutics that can address the full spectrum of KRAS-driven cancers. ETX-929 has demonstrated potent anti-tumor activity in preclinical models and has completed IND-enabling studies with anticipated IND clearance in Q2 2026.

About ETX-880

ETX-880 is a covalent, potent, oral inhibitor of Werner syndrome ATP-dependent helicase (WRN) designed leveraging ENSEM’s Kinetic Ensemble platform. WRN helicase has emerged as a compelling synthetic lethal target in microsatellite instability-high (MSI-H) cancers. MSI-H tumors arise from defects in the DNA mismatch repair pathway and are found across multiple tumor types, including colorectal, endometrial, gastric, and ovarian cancers. While immune checkpoint inhibitors have demonstrated clinical benefit in MSI-H cancers, 40–70% of patients either do not respond or eventually develop resistance, underscoring the need for novel therapeutic approaches. ETX-880’s covalent binding mechanism is designed to deliver deep and sustained WRN inhibition, and the compound has demonstrated selective anti-proliferative activity against MSI-H cancers in preclinical studies. ETX-880 is currently at the IND-enabling stage.

(Press release, ENSEM Therapeutics, APR 17, 2026, View Source [SID1234664502])

On April 17, 2026 Bruker Corporation (Nasdaq: BRKR) reported new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting. At AACR (Free AACR Whitepaper), Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At AACR (Free AACR Whitepaper) 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx DSP to CellScape XR and CellScape XR to CosMx SMI, enabling researchers integrate insights across its spatial biology portfolio—revealing biological relationships that cannot be captured with a single modality alone. Bruker Spatial Biology will also debut new 208‑plex datasets from CellScape XR, highlighting flexible subcellular proteomics for rapid, quantitative spatial phenotyping in oncology applications.

These announcements build upon the major spatial biology milestones Bruker introduced earlier this year at the AGBT General Meeting, where the company demonstrated a portfolio engineered for high-fidelity performance within each omic layer. Together, these advances reflect Bruker Spatial Biology’s long‑standing approach: advancing each platform to be best‑in‑class individually, while consistently being first to demonstrate what is possible when spatial data is captured with unmatched depth, resolution, and fidelity—and connected across biological layers.

PaintScape Now Open for Pre‑Orders with Shipments Expected This Quarter

With the PaintScape platform, Bruker is the only company enabling high‑precision, multiplexed, direct visualization of the 3D genome in situ in single cells. PaintScape enables researchers to study chromosomal architecture, spatial genome organization, and structural variation directly within intact biological context, opening new avenues for understanding how genome structure influences gene regulation and disease.

Bruker will launch two new panels for the PaintScape platform, including the ChromoPaint HuCL PanChromo MPX panel, a 419-plex panel designed for genome wide in situ visualization of chromosomal organization in human cell lines. In addition, Bruker will announce the OncoPaint Oncogenic Pathways Panels that will be available later this year, a 1000+-plex modular panel designed to combine genome wide chromosome painting with painting of select cancer pathway associated gene regions in increased genomic resolution.

Commercial shipments of the PaintScape platform are expected to begin later this quarter.

Introducing CellScape XR, the Highest Performing Spatial Proteomics Ecosystem Delivering Best-in-Class Data Fidelity, Robustness and Flexibility

The CellScape XR launch at AGBT represents Bruker’s next-generation advancement in spatial proteomics and introduces what is now the highest fidelity spatial proteomics platform, designed to deliver best‑in‑class data quality, robustness, and assay flexibility.

At AACR (Free AACR Whitepaper), Bruker Spatial Biology will showcase new 208‑plex spatial proteomics datasets, in collaboration with Niclas Blessin at University Medical Center Schleswig-Holstein (UKSH). This assay was pathology reviewed across 12 distinct neoplastic and non-neoplastic human FFPE tissue samples demonstrating the robustness of the CellScape XR protocol. These capabilities enable deeper interrogation of tumor biology, immune contexture, and signaling heterogeneity, and form a critical bridge between discovery‑scale profiling and translational research, at a scale and rigor required for clinical applications.

Bruker is accepting pre-orders for the CellScape XR, with commercial shipments expected this summer.

CosMx SMI Showcases and Extends Complete Spatial Biology Approach

Bruker has consistently been first to define what is possible with the CosMx SMI platform setting multiple best-in-class benchmarks—including both AI multimodal and 3D segmentation, subcellular spatial imaging of the human whole transcriptome (WTX), and same-cell multiomics (WTX and 64+ proteins). At AACR (Free AACR Whitepaper), Bruker Spatial Biology will showcase how these high fidelity, high sensitivity capabilities are expanding further—extending subcellular spatial imaging of the mouse whole transcriptome and highlighting emerging applications for studying human disease, such as T‑cell receptor (TCR) and miRNA imaging.

The AtoMx SIP builds on the unparalleled data richness of CosMx SMI to accelerate study‑level insight generation and biological interpretation. At AACR (Free AACR Whitepaper), Bruker Spatial Biology will reinforce a new spatial discovery workflow with AtoMx SIP, enabling rapid, image‑based exploration of single‑cell and subcellular whole transcriptome datasets through pre‑calculated spatial insights and streamlined data exports designed for conversational large language model (LLM) workflows. Applying LLMs to the comprehensive, high fidelity spatial data generated by CosMx SMI enables richer, higher quality outputs than are possible with lower resolution or lower content approaches, delivering a more interactive and intuitive experience for biological discovery. In addition, Bruker Spatial Biology will showcase new 3D AI‑based cell segmentation models that extend its best‑in‑class definition of single‑cell boundaries, improving RNA transcript assignment in tissue and addressing long standing limitations of segmentation approaches that fail to account for overlapping cells.

Bruker is accepting pre-orders for the Mouse CosMx WTX.

GeoMx Discovery Multiomics Platform Showcases Unmatched Spatial Biomarker Discovery at Scale with Whole Transcriptome and 1200+ Protein Targets

With GeoMx DSP, Bruker was the first to establish spatial biology at discovery scale and has continued to lead by demonstrating what is possible from discovery through translational research and clinically oriented applications. GeoMx DSP was first to enable high‑plex, same‑slide whole transcriptome and protein multiomics, and later to demonstrate spatial proteomic profiling of more than 1,200 antibodies on tissue with the Discovery Proteome Atlas. At AACR (Free AACR Whitepaper), Bruker Spatial Biology will showcase how GeoMx DSP is the only spatial platform to now simultaneously connect RNA pathway, protein, and post-translational modification (PTMs) across different layers of biology. The breadth of this spatial multiomics data is now informing researchers of biological pathways that are both transcriptionally active and driving functional response. GeoMx DSP further anchors large cohort biomarker and signature discovery and now connects seamlessly to downstream validation and spatial phenotyping workflows with CellScape XR on the same tissue section.

In addition to its spatial biology portfolio, Bruker will present complementary solutions including the nCounter Analysis System for bulk multiomics and the Beacon Platform, including Beacon Discovery, supporting downstream translational workflows and functional live single‑cell biology.

(Press release, Bruker, APR 17, 2026, View Source [SID1234664501])

On April 17, 2026 Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, reported expansion cohort data from the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic cancer, including non-small cell lung cancer (NSCLC) and breast cancer, which is being presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 on April 17-22, 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"JK06 continues to demonstrate encouraging and durable efficacy among heavily pre-treated metastatic solid tumors. Partial responses have now been observed across four different cancers, including NSCLC and breast cancer, at multiple dose levels. These data are complemented by a consistently favorable safety profile, underscoring our belief that JK06 has the potential to be an important new first-in-class ADC that can address the unmet needs of patients with 5T4-expressing cancers," said Sam Murphy, Chief Executive Officer of Salubris Biotherapeutics. "These results provide a robust foundation for further exploration of JK06 in NSCLC and breast cancer and will propel our efforts to interrogate the pan-tumor opportunity. We look forward to progressing this study into the next stages of expansion cohorts, including additional monotherapy cohorts and evaluation of JK06 in multiple combination therapy regimens."

Expansion cohort data presented at AACR (Free AACR Whitepaper) include 112 patients enrolled in Europe with advanced relapsed/refractory solid tumors who were treated with JK06 once every three weeks, including two randomized dose cohorts (3.7 mg/kg, 4.5 mg/kg) in NSCLC and breast cancer and a basket cohort consisting of multiple tumor types known to express 5T4. The data cutoff was March 29, 2026.

Key efficacy findings include:

Among 38 response-evaluable NSCLC patients, 10 attained confirmed PRs (ORR 26%), including three out of seven response-evaluable squamous cell NSCLC patients (ORR 43%), and two of three response-evaluable Epidermal Growth Factor Receptor (EGFR) mutant patients.
Five out of 19 response-evaluable breast cancer patients attained PRs (ORR 26%), including four out of nine hormone receptor-positive (HR+) breast cancer patients (ORR 44%).
Among other tumor types, the first and only response-evaluable gastric cancer patient enrolled attained a partial response (PR, -55%), and one of four response-evaluable cervical cancer patients attained a partial response (PR, -49%).
Among 112 safety-evaluable patients enrolled in expansion cohorts, key safety findings include:

Treatment with JK06 at doses ≤ 5.2 mg/kg was generally well-tolerated with predominantly low grade (Grades 1 and 2) treatment-related adverse events (TRAEs) and manageable toxicities.
All JK06-related AEs of any grade are below 10% frequency overall except for asthenia (11% overall).
Only three total Grade 3 events have been observed to date among the 112 patients (fatigue, gait disturbance, keratitis), and no Grade 4 or 5 events have been observed.
Of the total 153 patients enrolled across all dose levels in dose escalation and expansion, only seven patients have dose-reduced due to a TRAE resulting from JK06.

The Phase 1/2 open-label, dose-escalation and expansion study (NCT06667960) to assess the safety, pharmacokinetics, and preliminary efficacy of JK06 is ongoing.

Details of the AACR (Free AACR Whitepaper) presentation are as follows:

Title: A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), In Patients with Unresectable Locally Advanced or Metastatic Cancer
Presenter: Omar Saavedra, M.D., Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Abstract #: CT250
Session: Phase II Clinical Trials
Date/Time: April 21, 2026 | 2:00 – 5:00 PM PT

About JK06

JK06 is a first-in-class quadrivalent, biparatopic ADC that selectively targets 5T4 with a monomethyl auristatin E (MMAE) payload. 5T4 is an oncofetal protein that is overexpressed in a wide range of solid tumors, including non-small cell lung cancer (NSCLC), breast, gastric and genitourinary cancers, and is associated with more aggressive tumor progression and reduced survival. JK06 has demonstrated picomolar affinity for 5T4 and enhanced internalization resulting from the biparatopic design. Together with stable, site-specific payload conjugation, JK06 has demonstrated the potential for robust efficacy and a favorable safety profile.

(Press release, Salubris Biotherapeutics, APR 17, 2026, View Source [SID1234664500])

On April 17, 2026 OncoNano Medicine, Inc. ("OncoNano"), a clinical-stage biotechnology company developing precision therapies using its proprietary nanotechnology platform, reported it will present new preclinical data at the AACR (Free AACR Whitepaper) Annual Meeting 2026. The presentations highlight the breadth of its ON-BOARD platform and its ability to enable effective, tumor-targeted delivery of therapeutic payloads through clinically validated ultra pH-sensitive micelle technology designed to activate within the tumor microenvironment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our ON-BOARD platform is designed to overcome key limitations of existing delivery approaches, including reliance on tumor-associated antigens and off-tumor toxicities," said Kartik Krishnan, MD, PhD, Chief Executive Officer of OncoNano. "These data demonstrate the versatility of our platform across multiple payloads and reinforce its potential to deliver profound efficacy with an improved therapeutic index."

Poster Presentation Details

A Polymer-Drug Conjugate Platform for Tumor Specific Drug Delivery: Advancement of a Clinically Validated Ultra pH-Sensitive Micelle Technology
Presenter: Qingtai Su, PhD, Senior Scientist
Session Date/Time: April 20, 2026 | 2:00–5:00 PM PT
Location: Poster Section 14 | Board #17 | Poster #3026

This presentation highlights the breadth and tunability of the ON-BOARD platform, demonstrating tumor-specific delivery of multiple cytotoxic compounds through targeting the acidic tumor microenvironment. Preclinical data show strong in vitro and in vivo anti-tumor activity across a range of payload-linker combinations, including superior tumor growth inhibition and robust responses compared to standard-of-care agents. Findings further illustrate the ability to modulate payload release through linker design, supporting a differentiated, antigen-independent approach to drug delivery.

ONM-421, a pH-Responsive Polymer-Drug Conjugate Nanoparticle, Delivers MMAE to Solid Tumors and Shows Antigen-Independent Antitumor Efficacy in Mice
Presenter: Jason Miller, PhD, Associate Director
Session Date/Time: April 20, 2026 | 2:00–5:00 PM PT
Location: Poster Section 14 | Board #12 | Poster #3021

Building on the platform’s versatility, this presentation features ONM-421 as a lead example of ON-BOARD–enabled delivery. Preclinical findings demonstrate potent, antigen-independent anti-tumor efficacy across multiple xenograft models, including strong tumor growth inhibition and survival benefit. ONM-421 showed broader activity compared to an MMAE-based antibody-drug conjugate, including efficacy in tumors with low target expression where the ADC was less active. In these models, ONM-421 also demonstrated improved tolerability relative to a standard chemotherapy when given at an efficacious dose. These data highlight enhanced payload stability and protection during circulation, reinforcing the platform’s ability to enable targeted tumor delivery while reducing off-target toxicity.

(Press release, OncoNano Medicine, APR 17, 2026, View Source [SID1234664499])

On April 17, 2026 NEOK Bio, Inc., an oncology therapeutics company focused on the development of novel antibody drug conjugates (ADCs) for improving outcomes for cancer patients, reported that two poster presentations highlighting its ADC pipeline will be delivered at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 taking place April 17-22, 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) 2026 presentations will showcase NEOK’s emerging pipeline of next-generation ADCs engineered to target proteins broadly expressed across tumor types with high unmet need. The company will present new findings for its two lead bispecific candidates: NEOK001, a first-in-class "2+2" bispecific ADC designed to target B7-H3 and ROR1-expressing tumors, and NEOK002, a "1+1" bispecific ADC targeting EGFR (epidermal growth factor receptor) and MUC1 (Mucin 1)-expressing solid tumors. Both therapies utilize Synaffix’s proprietary, validated linker-payload technology with a DAR 4 Topoisomerase-1 (Topo-1) inhibitor, exatecan (SYNtecan E ).

Both programs have received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), and NEOK plans to initiate Phase 1 clinical trials in 2Q 2026, with initial clinical data readouts anticipated in 2027. Both of NEOK’s bispecific ADC candidates will enter the clinic on a foundation of promising preclinical studies, where they have demonstrated superior in vivo efficacy in solid tumors compared to traditional monovalent ADCs.

Preclinical data will be shared in two separate poster presentations on April 20 during the session titled "Antibody Drug Conjugates and Linker Engineering 2" at AACR (Free AACR Whitepaper) 2026. Highlights of the presentations include:

Poster 1724: NEOK001: A first-in-class B7-H3xROR1 bispecific ADC demonstrated enhanced efficacy and promising tolerability

Potent dual‑target cytotoxicity and strong bystander killing, supporting activity in heterogeneous solid tumors
Broad efficacy across 38 PDX models, achieving 84% tumor growth inhibition and 53% deep tumor regression across nine major cancer types
Outperformed clinical benchmark ADCs, including I‑Dxd and zilovertamab vedotin, and successfully regressed I‑Dxd-treated regrowing tumors
Observed favorable safety profile in GLP toxicology studies (HNSTD: 60 mg/kg) with stable DAR and predictable pharmacokinetics
Poster 1726: NEOK002: Designing an EGFRxMUC1 Bispecific TOP1i ADC with Promising Anti-Tumor Activity and Enhanced Therapeutic Window

Dual-targeting design enhances binding and internalization in dual-positive tumor cells while reducing off‑tumor EGFR engagement
Robust antitumor activity across 36 PDX models, achieving tumor regressions in 78%, including KRAS‑mutant and heavily pretreated tumors
Favorable safety profile with minimal impact on keratinocyte proliferation and reduced inhibition of EGFR signaling versus cetuximab-based ADCs
Strong combination potential sotorasib, enabling extended tumor regression for 58 days in KRAS G12C-mutant models
"These preclinical findings underscore the potential of our next-generation ADC pipeline to overcome the limitations of conventional monovalent designs," said Mayank Gandhi, MD, CEO of NEOK Bio. "As we prepare to accelerate both candidates into clinical development, we look forward to sharing their differentiated mechanisms and compelling pre-clinical activity at ACCR 2026."

(Press release, Neok Bio, APR 17, 2026, View Source [SID1234664498])